{
    "clinical_study": {
        "@rank": "154889", 
        "arm_group": [
            {
                "arm_group_label": "oral ibuprofen", 
                "arm_group_type": "Active Comparator", 
                "description": "Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later"
            }, 
            {
                "arm_group_label": "normal saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the effectiveness of conservative management versus\n      conventional ibuprofen treatment for patent ductus arteriosus in preterm infants. The study\n      hypothesis is that conservative management is not inferior to oral ibuprofen treatment in\n      preterm infants."
        }, 
        "brief_title": "Conservative Management for Patent Ductus Arteriosus in Preterm Infants", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Bronchopulmonary Dysplasia", 
        "condition_browse": {
            "mesh_term": [
                "Bronchopulmonary Dysplasia", 
                "Ductus Arteriosus, Patent"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. gestational age of 30 weeks or less or birth weight of 1250 g or less\n\n          2. born in Samsung Medical Center\n\n          3. confirmed to have hemodynamically significant patent ductus arteriosus (PDA) during\n             day of life (DOL) 7 to 14\n\n          4. Definition of hemodynamically significant PDA: at least one of clinical criteria plus\n             at least one of echocardiographic criteria\n\n               -  Clinical criteria\n\n                    -  Respiratory signs, including tachypnea, chest retraction, increased\n                       respiratory support, unable to wean respiratory support\n\n                    -  Physical signs, including a murmur, hyperdynamic precordium or bounding\n                       pulses\n\n                    -  Blood pressure problems, including decreased mean or diastolic pressure or\n                       increased pulse pressure\n\n                    -  Signs of congestive heart failure, including cardiomegaly, hepatomegaly or\n                       pulmonary congestion\n\n               -  Echocardiographic criteria\n\n                    -  Ductal size \u2265 1.5 mm\n\n                    -  left atrium (LA)/Aorta ratio \u22651.5:1\n\n                    -  Left-to-right shunting or bidirectional shunting with dominant\n                       left-to-right blood flow (the presence of a color jet in the mean pulmonary\n                       artery)\n\n        Exclusion Criteria:\n\n          -  Mortality within the first 48 hours of life\n\n          -  Right-to-left shunt or bidirectional shunting with dominant right-to-left shunt\n             through PDA\n\n          -  congenital anomaly\n\n          -  bilateral intraventricular hemorrhage of grade 4\n\n          -  contraindication of ibuprofen (bleeding diasthesis, platelet count 10,000/mm3 or\n             less, serum creatinine 2.0 mg/dL or greater, necrotizing enterocolitis stage 2 or\n             greater"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "14 Days", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "142", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128191", 
            "org_study_id": "2013-07-129"
        }, 
        "intervention": [
            {
                "arm_group_label": "oral ibuprofen", 
                "intervention_name": "Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "normal saline", 
                "intervention_name": "Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ibuprofen"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Patent ductus arteriosus", 
            "Ibuprofen", 
            "Bronchopulmonary dysplasia"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "sein.sung@samsung.com", 
                "last_name": "Se In Sung, M.D.", 
                "phone": "82-2-3410-1775"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "135-710"
                }, 
                "name": "Samsung Medical Center"
            }, 
            "investigator": {
                "last_name": "Se In Sung, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Conservative Management for Patent Ductus Arteriosus in Preterm Infants: a Double-blind, Randomized, Placebo-controlled Trial", 
        "overall_contact": {
            "email": "sein.sung@samsung.com", 
            "last_name": "Se In Sung, M.D.", 
            "phone": "82-2-3410-1775"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Se In Sung, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of moderate to severe bronchopulmonary dysplasia (BPD) or mortality at 36 weeks postmenstrual age (PMA)", 
            "safety_issue": "No", 
            "time_frame": "36 weeks PMA"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128191"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Se In Sung", 
            "investigator_title": "M.D.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of BPD", 
                "safety_issue": "No", 
                "time_frame": "28-days since birth"
            }, 
            {
                "measure": "Incidence of oxygen dependency at 40 weeks PMA", 
                "safety_issue": "No", 
                "time_frame": "40 weeks PMA"
            }, 
            {
                "measure": "Mortality rate", 
                "safety_issue": "No", 
                "time_frame": "28-days since birth and 36 weeks PMA"
            }, 
            {
                "measure": "incidence of intraventricular hemorrhage (grade 3 or greater)", 
                "safety_issue": "No", 
                "time_frame": "28-days since birth"
            }, 
            {
                "measure": "Incidence of retinopathy of prematurity (stage III or greater)", 
                "safety_issue": "No", 
                "time_frame": "40 weeks PMA (\u00b1 2 weeks)"
            }, 
            {
                "measure": "Incidence of necrotizing enterocolitis (stage 2b or greater)", 
                "safety_issue": "No", 
                "time_frame": "40 weeks PMA (\u00b1 2 weeks)"
            }, 
            {
                "measure": "Duration of PDA", 
                "safety_issue": "No", 
                "time_frame": "40 weeks PMA (\u00b1 2 weeks)"
            }, 
            {
                "measure": "Duration of intubation", 
                "safety_issue": "No", 
                "time_frame": "36 weeks PMA"
            }, 
            {
                "measure": "Duration of nasal continuous positive airway pressure (NCPAP) treatment", 
                "safety_issue": "No", 
                "time_frame": "40 weeks PMA (\u00b1 2 weeks)"
            }, 
            {
                "measure": "Cumulative duration of oxygen use", 
                "safety_issue": "No", 
                "time_frame": "40 weeks PMA (\u00b1 2 weeks)"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of hospital stay, an expected average of 12 weeks"
            }, 
            {
                "measure": "Growth velocity", 
                "safety_issue": "No", 
                "time_frame": "40 weeks PMA (\u00b1 2 weeks)"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}